CytoMed Therapeutics Limited is accelerating its international expansion

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, The company announced that its wholly-owned subsidiary established in 2020, Advance Cancer Centre Pte. Ltd., has changed its name to CytoMed International Pte. Ltd. ("CytoMed International"), effective May 6, 2026.

The name change reflects the Company's renewed focus on exploring opportunities to expand its international footprint, including setting up joint ventures overseas, development of international medical tourism initiatives, appointment of overseas representatives and enhancing its profile overseas. Initial geographical focus will be in Asia, especially China.

CytoMed International's sole asset currently consists of a 19.0% equity interest in a licenced clinic in Malaysia, with an option to increase its shareholding in the future.

The name change does not affect the CytoMed International's legal entity, ownership structure, or existing contractual obligations.

More details regarding the company's international business plan will be provided as soon as possible. Meanwhile the Company will use its internal resources to support CytoMed International's operations.

Incorporated in 2018, CytoMed is a biotech company spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector, and focused on translating its proprietary technologies into cell-based immunotherapy cancer treatments. The development of these novel technologies was inspired by the clinical success of chimeric antigen receptor-modified T (CAR-T) cells in treating hematological malignancies and introduces solutions for the clinical limitations and commercial challenges inherent in extrapolating the CAR-T principle into treatments for solid tumors.

The development of CD19-targeting CAR-T cells to treat B-cell malignancies underscores cellular immunotherapy's increasingly essential role in cancer care. However, the therapies in use today face several challenges that include: reliance on a patient's limited cell quality and quantity, the lack of "safe" surface cancer antigens and their recognition system, and the limited success rate of relying on a single antigen-targeting strategy. Applying the current CAR-T principle when treating other types of cancers, particularly solid tumors, can be challenging. To this end, we have established two novel, patent-pending patient blood cell-independent therapies to manufacture "off-the-shelf" cell-based cancer immunotherapies: one treatment innovating the CAR-T cell approach and another generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using our proprietary technologies.
• Donor blood cell-based technology (CTM-N2D therapy* & CTM-N2D therapy)
• iPSC-derived technology (iPSC-?? gdNKT therapy*)
Fn: * patent-pending therapies

These therapies exploit the multiple-antigen recognition systems of both natural killer (NK) cells and ?? T cells and may be used to recognize and treat a broad range of cancers.

Ms Evelyn
CytoMed Therapeutics Ltd
Singapore
https://www.cytomed.sg/

The cellular therapies will be manufactured for clinical trials at a cGMP facility in Johor, Malaysia (near Singapore), in a facility built in accordance with the international PIC/S GMP Standards. The company will directly oversee manufacturing with a well-trained, professional team conducting all essential GMP activities, including manufacture, QC, QA, and documentation.

This release was published on openPR.